Sachetta LLC Sells 250 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Sachetta LLC decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 21.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 932 shares of the company’s stock after selling 250 shares during the period. Sachetta LLC’s holdings in CRISPR Therapeutics were worth $37,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of CRSP. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics in the third quarter worth $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics in the third quarter worth $43,000. Eastern Bank purchased a new position in CRISPR Therapeutics during the third quarter valued at $70,000. Finally, MCF Advisors LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $80,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Bank of America lowered their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Barclays reduced their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $43.42 on Friday. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -15.34 and a beta of 1.68. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $91.10. The business’s fifty day moving average price is $44.30 and its 200-day moving average price is $47.73.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the company earned ($1.41) earnings per share. Equities research analysts anticipate that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.